JAGSNPHARM share price, P/E, ROE & financials

On 6 Nov 2026, Jagsonpal Pharmaceuticals was priced at ₹213.21, or 32.0× trailing earnings, against an industry P/E of 28.7×, and the shares are 19% below their 52-week high. Sales and net profit grew 6.7% and 17% a year over 3 years; its ROCE of 20% is the highest among the 7 largest Drug Manufacturers (Specialty & Generic) peers. It carries very little debt, and its dividend yield is 1.2%. It is a small-cap company with a market cap of ₹1,408 Cr, ranked 65th of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares rose 1.5% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Sep 2026.How we calculate this

past year

Open: ₹221.60
Day high: ₹221.60
Day low: ₹209.76
Prev. close: ₹219.89
Volume: 94.3K

Health check

2 good · 2 fair · 2 to check

ReturnsBehind
+1.5% over a year, better than 1 of 7 peers.
Price tagIn line
P/E 32.0 vs industry 28.7.
GrowthSteady
Sales +6.7%, profit +17.3% a year over 3 years.
ProfitabilityStrong
ROCE 20.2% vs peer median 17.9%.
Balance sheetStretched
Practically debt-free, Piotroski 2 of 9.
Red flagsNone found
No warning signs in the headline numbers.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Small cap

₹1,408 Cr, #65 of 154 in its industry by size.

Market sensitivity

Measuring against the NIFTY 50…

Key metrics

Last 12 months to Sep 2026: sales ₹316 Cr · profit ₹45 Cr

Market cap: ₹1,408 Cr; Small cap
P/E: 32.0; Industry 28.7
Price to book: 5.85; Peers 4.99
Dividend yield: 1.17%
ROE: 18.2%; Peers 14.7%
ROCE: 20.2%; Peers 17.9%
Debt to equity: 0.04; Debt ₹9.22 Cr
EPS (TTM): ₹6.67; Face value ₹2
OPM (TTM): 19.5%; Net margin 14.3%
Sales growth: +29.4%; Latest quarter vs a year ago
Profit growth: −2.3%; Latest quarter vs a year ago
Price to sales: 4.46; EV/EBITDA 21.8

Strengths

Return on equity of 18.2%.
Return on capital employed of 20.2%.
Practically debt-free.
Quarterly sales up 29.4% on a year ago.
Positive operating cash flow in each of the last 4 years.

No obvious red flags in the headline numbers.

Derived automatically from reported figures. Not a recommendation.

About Jagsonpal Pharmaceuticals

Jagsonpal Pharmaceuticals Limited engages in the manufacturing, selling, and trading of pharmaceutical products and active pharmaceutical ingredients in India and internationally. It offers pharmaceutical formulations and products in the areas of gynaecology, orthopaedics, dermatology, and paediatrics. The company provides drugs in the form of tablets, softgels, injections, capsules, and syrups. Jagsonpal Pharmaceuticals Limited was incorporated in 1978…

Headquarters: Gurugram
Employees: 1,297
Sector: Healthcare
ISIN: INE048B01035
Website: jagsonpal.com

Price range

52 weeks

₹155.00₹264.50

Today

₹209.76₹221.60

Avg volume (3M): 2.5 L
1-year return: plus 1.5%
From 52-week high: minus 19.4%

Peers · Drug Manufacturers - Specialty & Generic

Compare with peers Screen the whole industry

Company
SUNPHARMASun Pharmaceutical Industries	1,860.00	plus 1.69%	4,46,276	40.7	4.99	17.9%	13.1%	28.2%	10.4%	10.6%	0.86%	plus 8.2%
DIVISLABDivi's Laboratories	10,320.50	plus 1.78%	2,73,977	93.6	16.35	19.0%	16.2%	34.9%	11.0%	12.1%	0.29%	plus 49.0%
TORNTPHARMTorrent Pharmaceuticals	4,750.00	plus 0.85%	1,80,675	80.2	9.83	9.1%	15.7%	33.7%	13.3%	20.2%	0.80%	plus 31.7%
LAURUSLABSLaurus Labs	2,340.00	minus 0.26%	1,26,433	94.4	20.86	19.5%	24.0%	30.4%	3.8%	4.0%	0.09%	plus 138.6%
ZYDUSLIFEZydus Lifesciences	1,197.90	plus 0.41%	1,19,491	28.6	4.29	19.0%	14.7%	26.2%	16.5%	37.0%	0.08%	plus 22.8%
DRREDDYDr. Reddy's Laboratories	1,373.00	plus 0.51%	1,14,462	40.9	2.96	14.2%	7.3%	15.9%	11.0%	−1.7%	0.58%	plus 13.8%
CIPLACipla	1,411.00	plus 0.49%	1,13,993	39.4	3.22	14.9%	8.3%	17.3%	7.2%	11.5%	0.92%	minus 6.6%
JAGSNPHARMJagsonpal Pharmaceuticals	213.21	minus 3.04%	1,408	32.0	5.85	20.2%	18.2%	15.2%	6.7%	17.3%	1.17%	plus 1.5%
Median of 7 peers	–	0.51%	1,26,433	40.9	4.99	17.9%	14.7%	28.2%	11.0%	11.5%	0.58%	22.8%

Quarterly results

Consolidated, ₹ crore

SalesSelect a row below to chart it

Sep 25	Dec 25	Mar 26	Jun 26	Sep 26
74.5	72.9	64.2	82.2	96.4
58	56.7	53	65	79.5
16.4	16.3	11.2	17.2	16.9
22.1%	22.3%	17.4%	21.0%	17.5%
3	3	3.2	2.8	2.3
0.3	0.3	0.3	0.3	0.3
2.4	2.4	2.3	2.1	2.2
–	−2.1	–	–	−0.2
16.8	14.5	11.8	17.7	16.4
25.2%	24.6%	25.5%	25.4%	25.2%
12.6	11	8.8	13.2	12.3
1.87	1.65	1.21	1.98	1.83

Profit & loss

Yearly, ₹ crore

Sales CAGR 3Y: +6.7%
Profit CAGR 3Y: +17.3%
EPS CAGR 3Y: +15.6%
ROE: 18.2%

Net profitSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
237	209	269	287
–	minus 11.8%	+28.8%	+6.9%
201	185	218	229
35.5	23.3	51.1	58.1
15.0%	11.1%	19.0%	20.2%
3.7	9	8.1	11.8
0.3	0.8	0.9	0.8
1.2	1.7	8.1	9.4
−3	–	19.7	−2.1
34.8	29.9	69.9	57.5
23.2%	24.8%	20.8%	25.1%
26.7	22.5	55.4	43.1
–	minus 15.9%	+146.5%	minus 22.2%
4.08	3.39	8.22	6.31

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore

Total assetsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
13.1	13.2	13.3	13.4
146	174	227	263
6	8.9	9.2	8.2
30.1	20.7	29.1	32.3
195	217	278	317
24.3	9.3	8.8	7.4
3.4	4.7	17.4	84.5
115	148	129	106
52.6	55.1	123	119
195	217	278	317

Cash flow

Yearly, ₹ crore

Cash from operationsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
46.7	35.2	55.1	46.8
−57.7	−24.5	−45.1	−35.6
−0.5	−8.9	−11.7	−12.1
−11.5	1.7	−1.7	−1
−0.3	−0.2	−0.3	−0.1
46.3	34.9	54.8	46.7
–	−13.1	−13.2	−16.7

Shareholding pattern

Source: NSE filings

68.8%

promoters

Promoters68.81%
Public31.19%
As of 30 Sep 2026

Quarter	Promoters	Public	Promoter change
30 Sep 2026	68.81%	31.19%	minus 0.24
30 Jun 2026	69.05%	30.95%	minus 0.31
2 Jun 2026	69.36%	30.64%	plus 1.47
31 Mar 2026	67.89%	32.11%	plus 0.50
31 Dec 2025	67.39%	32.61%	–

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you